Trial Profile
A Double-blind, Placebo Controlled Evaluation of the Efficacy, Safety and Tolerability of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors BioDelivery Sciences International
- 25 Nov 2009 Full and final results available in Annals of Oncology, published in advance online.
- 03 Jun 2008 Results were presented at the 44th Annual Meeting of the American Society of Clinical Oncology.
- 09 May 2008 Results presented at the American Pain Society Annual Meeting held in May 2008.